Jun 09, 2021 / 08:40PM GMT
Kyuwon Choi - Goldman Sachs Group, Inc., Research Division - Equity Analyst
Okay. We'll continue with the next session. Thank you, everyone, for joining us here at day 2 of the 42nd Annual Goldman Sachs Global Healthcare Conference. Our next session will be with NGM, and we're joined by the management there, David Woodhouse, CEO; and Siobhan Mangini, CFO. As with prior sessions, what we'll do is turn it over to David for some introductory comments, and then we'll go into Q&A. If along the way, if any clients have questions for the management team here, please feel free to submit them through the webcast portal. Alternatively, you can e-mail them to me. And time permitting, I will read them out loud to the company. But otherwise, with that, I'll turn it over to David for some opening comments.
David J. Woodhouse - NGM Biopharmaceuticals, Inc. - CEO & Director
Sure. Thanks for the invitation to the conference, Paul. Maybe just to orient people on NGM, if you're not familiar with the company, we are a biologics discovery platform that has been quite
NGM Biopharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 10, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers